InNexus Biotechnology, Inc. (IXSBF) Stock Competitors & Peer Comparison
See (IXSBF) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| IXSBF | $0.00 | +0.00% | 12.6K | -0.01 | -$0.01 | N/A |
| ALBHF | $0.46 | -4.17% | 7.4B | 23.00 | $0.02 | N/A |
| ALBBY | $9.05 | -2.37% | 7.3B | 25.86 | $0.35 | N/A |
| MSMKF | $18.17 | +0.00% | 7.2B | 19.75 | $0.92 | +1.73% |
| RGEDF | $38.66 | -0.03% | 7.1B | 9.27 | $4.17 | +5.55% |
| RADLY | $3.44 | -2.62% | 6B | 21.50 | $0.16 | +2.18% |
| DCHPF | $46.90 | -0.21% | 5.3B | -151.29 | -$0.31 | N/A |
| GEDSF | $24.85 | +0.00% | 4.5B | 10.71 | $2.32 | +8.62% |
| TSUSF | $17.25 | +0.00% | 4.2B | 41.07 | $0.42 | +6.12% |
| WLCGF | $16.41 | +0.00% | 3.4B | 19.54 | $0.84 | +1.47% |
Stock Comparison
IXSBF vs ALBHF Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, ALBHF has a market cap of 7.4B. Regarding current trading prices, IXSBF is priced at $0.00, while ALBHF trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas ALBHF's P/E ratio is 23.00. In terms of profitability, IXSBF's ROE is +1.90%, compared to ALBHF's ROE of +0.17%. Regarding short-term risk, IXSBF is more volatile compared to ALBHF. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check ALBHF's competition here
IXSBF vs ALBBY Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, ALBBY has a market cap of 7.3B. Regarding current trading prices, IXSBF is priced at $0.00, while ALBBY trades at $9.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas ALBBY's P/E ratio is 25.86. In terms of profitability, IXSBF's ROE is +1.90%, compared to ALBBY's ROE of +0.17%. Regarding short-term risk, IXSBF is more volatile compared to ALBBY. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check ALBBY's competition here
IXSBF vs MSMKF Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, MSMKF has a market cap of 7.2B. Regarding current trading prices, IXSBF is priced at $0.00, while MSMKF trades at $18.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas MSMKF's P/E ratio is 19.75. In terms of profitability, IXSBF's ROE is +1.90%, compared to MSMKF's ROE of +0.11%. Regarding short-term risk, IXSBF is more volatile compared to MSMKF. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check MSMKF's competition here
IXSBF vs RGEDF Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, RGEDF has a market cap of 7.1B. Regarding current trading prices, IXSBF is priced at $0.00, while RGEDF trades at $38.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas RGEDF's P/E ratio is 9.27. In terms of profitability, IXSBF's ROE is +1.90%, compared to RGEDF's ROE of +0.17%. Regarding short-term risk, IXSBF is more volatile compared to RGEDF. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check RGEDF's competition here
IXSBF vs RADLY Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, RADLY has a market cap of 6B. Regarding current trading prices, IXSBF is priced at $0.00, while RADLY trades at $3.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas RADLY's P/E ratio is 21.50. In terms of profitability, IXSBF's ROE is +1.90%, compared to RADLY's ROE of +0.18%. Regarding short-term risk, IXSBF is more volatile compared to RADLY. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check RADLY's competition here
IXSBF vs DCHPF Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, DCHPF has a market cap of 5.3B. Regarding current trading prices, IXSBF is priced at $0.00, while DCHPF trades at $46.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas DCHPF's P/E ratio is -151.29. In terms of profitability, IXSBF's ROE is +1.90%, compared to DCHPF's ROE of -0.04%. Regarding short-term risk, IXSBF is more volatile compared to DCHPF. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check DCHPF's competition here
IXSBF vs GEDSF Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, GEDSF has a market cap of 4.5B. Regarding current trading prices, IXSBF is priced at $0.00, while GEDSF trades at $24.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas GEDSF's P/E ratio is 10.71. In terms of profitability, IXSBF's ROE is +1.90%, compared to GEDSF's ROE of +0.17%. Regarding short-term risk, IXSBF is more volatile compared to GEDSF. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check GEDSF's competition here
IXSBF vs TSUSF Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, TSUSF has a market cap of 4.2B. Regarding current trading prices, IXSBF is priced at $0.00, while TSUSF trades at $17.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas TSUSF's P/E ratio is 41.07. In terms of profitability, IXSBF's ROE is +1.90%, compared to TSUSF's ROE of +0.10%. Regarding short-term risk, IXSBF is more volatile compared to TSUSF. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check TSUSF's competition here
IXSBF vs WLCGF Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, WLCGF has a market cap of 3.4B. Regarding current trading prices, IXSBF is priced at $0.00, while WLCGF trades at $16.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas WLCGF's P/E ratio is 19.54. In terms of profitability, IXSBF's ROE is +1.90%, compared to WLCGF's ROE of +0.07%. Regarding short-term risk, IXSBF is more volatile compared to WLCGF. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check WLCGF's competition here
IXSBF vs CLCGY Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, CLCGY has a market cap of 3.3B. Regarding current trading prices, IXSBF is priced at $0.00, while CLCGY trades at $28.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas CLCGY's P/E ratio is 16.30. In terms of profitability, IXSBF's ROE is +1.90%, compared to CLCGY's ROE of +0.49%. Regarding short-term risk, IXSBF is more volatile compared to CLCGY. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check CLCGY's competition here
IXSBF vs SDGCF Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, SDGCF has a market cap of 3.3B. Regarding current trading prices, IXSBF is priced at $0.00, while SDGCF trades at $28.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas SDGCF's P/E ratio is 17.40. In terms of profitability, IXSBF's ROE is +1.90%, compared to SDGCF's ROE of +0.11%. Regarding short-term risk, IXSBF is more volatile compared to SDGCF. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check SDGCF's competition here
IXSBF vs SGIPF Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, SGIPF has a market cap of 2.9B. Regarding current trading prices, IXSBF is priced at $0.00, while SGIPF trades at $16.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas SGIPF's P/E ratio is 20.11. In terms of profitability, IXSBF's ROE is +1.90%, compared to SGIPF's ROE of +0.11%. Regarding short-term risk, IXSBF is more volatile compared to SGIPF. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check SGIPF's competition here
IXSBF vs CSMYF Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, CSMYF has a market cap of 2.9B. Regarding current trading prices, IXSBF is priced at $0.00, while CSMYF trades at $37.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas CSMYF's P/E ratio is 15.00. In terms of profitability, IXSBF's ROE is +1.90%, compared to CSMYF's ROE of +0.12%. Regarding short-term risk, IXSBF is more volatile compared to CSMYF. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check CSMYF's competition here
IXSBF vs SAEYY Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, SAEYY has a market cap of 1.1B. Regarding current trading prices, IXSBF is priced at $0.00, while SAEYY trades at $5.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas SAEYY's P/E ratio is -25.00. In terms of profitability, IXSBF's ROE is +1.90%, compared to SAEYY's ROE of -0.08%. Regarding short-term risk, IXSBF is more volatile compared to SAEYY. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check SAEYY's competition here
IXSBF vs SHPPF Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, SHPPF has a market cap of 919M. Regarding current trading prices, IXSBF is priced at $0.00, while SHPPF trades at $45.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas SHPPF's P/E ratio is -20.82. In terms of profitability, IXSBF's ROE is +1.90%, compared to SHPPF's ROE of -0.08%. Regarding short-term risk, IXSBF is more volatile compared to SHPPF. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check SHPPF's competition here
IXSBF vs HTSUY Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, HTSUY has a market cap of 839M. Regarding current trading prices, IXSBF is priced at $0.00, while HTSUY trades at $2.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas HTSUY's P/E ratio is N/A. In terms of profitability, IXSBF's ROE is +1.90%, compared to HTSUY's ROE of +0.07%. Regarding short-term risk, IXSBF is more volatile compared to HTSUY. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check HTSUY's competition here
IXSBF vs BJTRF Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, BJTRF has a market cap of 542.8M. Regarding current trading prices, IXSBF is priced at $0.00, while BJTRF trades at $0.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas BJTRF's P/E ratio is 8.10. In terms of profitability, IXSBF's ROE is +1.90%, compared to BJTRF's ROE of +0.13%. Regarding short-term risk, IXSBF is more volatile compared to BJTRF. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check BJTRF's competition here
IXSBF vs MYCOF Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, MYCOF has a market cap of 117.1M. Regarding current trading prices, IXSBF is priced at $0.00, while MYCOF trades at $2.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas MYCOF's P/E ratio is 1.10. In terms of profitability, IXSBF's ROE is +1.90%, compared to MYCOF's ROE of -0.14%. Regarding short-term risk, IXSBF is more volatile compared to MYCOF. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check MYCOF's competition here
IXSBF vs NVACF Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, NVACF has a market cap of 78.5M. Regarding current trading prices, IXSBF is priced at $0.00, while NVACF trades at $1.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas NVACF's P/E ratio is 31.60. In terms of profitability, IXSBF's ROE is +1.90%, compared to NVACF's ROE of +0.06%. Regarding short-term risk, IXSBF is more volatile compared to NVACF. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check NVACF's competition here
IXSBF vs ETBI Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, ETBI has a market cap of 6.2M. Regarding current trading prices, IXSBF is priced at $0.00, while ETBI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas ETBI's P/E ratio is -0.30. In terms of profitability, IXSBF's ROE is +1.90%, compared to ETBI's ROE of +0.41%. Regarding short-term risk, IXSBF is more volatile compared to ETBI. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check ETBI's competition here
IXSBF vs HEWA Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, HEWA has a market cap of 5.9M. Regarding current trading prices, IXSBF is priced at $0.00, while HEWA trades at $0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas HEWA's P/E ratio is -13.80. In terms of profitability, IXSBF's ROE is +1.90%, compared to HEWA's ROE of +0.08%. Regarding short-term risk, IXSBF is more volatile compared to HEWA. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check HEWA's competition here
IXSBF vs FFLWF Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, FFLWF has a market cap of 5.4M. Regarding current trading prices, IXSBF is priced at $0.00, while FFLWF trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas FFLWF's P/E ratio is -0.08. In terms of profitability, IXSBF's ROE is +1.90%, compared to FFLWF's ROE of -0.97%. Regarding short-term risk, IXSBF is more volatile compared to FFLWF. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check FFLWF's competition here
IXSBF vs SYDRF Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, SYDRF has a market cap of 2.9M. Regarding current trading prices, IXSBF is priced at $0.00, while SYDRF trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas SYDRF's P/E ratio is 10.00. In terms of profitability, IXSBF's ROE is +1.90%, compared to SYDRF's ROE of -0.42%. Regarding short-term risk, IXSBF is more volatile compared to SYDRF. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check SYDRF's competition here
IXSBF vs GABLF Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, GABLF has a market cap of 2.7M. Regarding current trading prices, IXSBF is priced at $0.00, while GABLF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas GABLF's P/E ratio is -0.04. In terms of profitability, IXSBF's ROE is +1.90%, compared to GABLF's ROE of +2.91%. Regarding short-term risk, IXSBF is more volatile compared to GABLF. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check GABLF's competition here
IXSBF vs RLLVF Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, RLLVF has a market cap of 2M. Regarding current trading prices, IXSBF is priced at $0.00, while RLLVF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas RLLVF's P/E ratio is -0.60. In terms of profitability, IXSBF's ROE is +1.90%, compared to RLLVF's ROE of +2.21%. Regarding short-term risk, IXSBF is more volatile compared to RLLVF. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check RLLVF's competition here
IXSBF vs PNPL Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, PNPL has a market cap of 1.9M. Regarding current trading prices, IXSBF is priced at $0.00, while PNPL trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas PNPL's P/E ratio is -2.60. In terms of profitability, IXSBF's ROE is +1.90%, compared to PNPL's ROE of +0.10%. Regarding short-term risk, IXSBF is more volatile compared to PNPL. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check PNPL's competition here
IXSBF vs IWINF Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, IWINF has a market cap of 1.7M. Regarding current trading prices, IXSBF is priced at $0.00, while IWINF trades at $0.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas IWINF's P/E ratio is -0.06. In terms of profitability, IXSBF's ROE is +1.90%, compared to IWINF's ROE of -0.21%. Regarding short-term risk, IXSBF is more volatile compared to IWINF. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check IWINF's competition here
IXSBF vs LGNZZ Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, LGNZZ has a market cap of 1.2M. Regarding current trading prices, IXSBF is priced at $0.00, while LGNZZ trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas LGNZZ's P/E ratio is N/A. In terms of profitability, IXSBF's ROE is +1.90%, compared to LGNZZ's ROE of +0.16%. Regarding short-term risk, IXSBF is more volatile compared to LGNZZ. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check LGNZZ's competition here
IXSBF vs BIEI Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, BIEI has a market cap of 1.1M. Regarding current trading prices, IXSBF is priced at $0.00, while BIEI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas BIEI's P/E ratio is -0.11. In terms of profitability, IXSBF's ROE is +1.90%, compared to BIEI's ROE of +0.03%. Regarding short-term risk, IXSBF is more volatile compared to BIEI. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check BIEI's competition here
IXSBF vs NUTTQ Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, NUTTQ has a market cap of 1.1M. Regarding current trading prices, IXSBF is priced at $0.00, while NUTTQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas NUTTQ's P/E ratio is N/A. In terms of profitability, IXSBF's ROE is +1.90%, compared to NUTTQ's ROE of +3.01%. Regarding short-term risk, IXSBF is more volatile compared to NUTTQ. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check NUTTQ's competition here
IXSBF vs LGNYZ Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, LGNYZ has a market cap of 741.5K. Regarding current trading prices, IXSBF is priced at $0.00, while LGNYZ trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas LGNYZ's P/E ratio is N/A. In terms of profitability, IXSBF's ROE is +1.90%, compared to LGNYZ's ROE of +0.16%. Regarding short-term risk, IXSBF is more volatile compared to LGNYZ. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check LGNYZ's competition here
IXSBF vs CNBI Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, CNBI has a market cap of 686.8K. Regarding current trading prices, IXSBF is priced at $0.00, while CNBI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas CNBI's P/E ratio is N/A. In terms of profitability, IXSBF's ROE is +1.90%, compared to CNBI's ROE of +0.17%. Regarding short-term risk, IXSBF is more volatile compared to CNBI. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check CNBI's competition here
IXSBF vs CAFS Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, CAFS has a market cap of 670.8K. Regarding current trading prices, IXSBF is priced at $0.00, while CAFS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas CAFS's P/E ratio is 0.35. In terms of profitability, IXSBF's ROE is +1.90%, compared to CAFS's ROE of +1.94%. Regarding short-term risk, IXSBF is more volatile compared to CAFS. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check CAFS's competition here
IXSBF vs RADCQ Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, RADCQ has a market cap of 559.7K. Regarding current trading prices, IXSBF is priced at $0.00, while RADCQ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas RADCQ's P/E ratio is -0.00. In terms of profitability, IXSBF's ROE is +1.90%, compared to RADCQ's ROE of +3.01%. Regarding short-term risk, IXSBF is more volatile compared to RADCQ. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check RADCQ's competition here
IXSBF vs MMDCF Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, MMDCF has a market cap of 541.2K. Regarding current trading prices, IXSBF is priced at $0.00, while MMDCF trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas MMDCF's P/E ratio is N/A. In terms of profitability, IXSBF's ROE is +1.90%, compared to MMDCF's ROE of N/A. Regarding short-term risk, IXSBF is more volatile compared to MMDCF. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check MMDCF's competition here
IXSBF vs AEGY Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, AEGY has a market cap of 411.2K. Regarding current trading prices, IXSBF is priced at $0.00, while AEGY trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas AEGY's P/E ratio is N/A. In terms of profitability, IXSBF's ROE is +1.90%, compared to AEGY's ROE of +0.00%. Regarding short-term risk, IXSBF is more volatile compared to AEGY. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check AEGY's competition here
IXSBF vs IPAH Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, IPAH has a market cap of 270.8K. Regarding current trading prices, IXSBF is priced at $0.00, while IPAH trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas IPAH's P/E ratio is -0.05. In terms of profitability, IXSBF's ROE is +1.90%, compared to IPAH's ROE of -0.82%. Regarding short-term risk, IXSBF is more volatile compared to IPAH. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check IPAH's competition here
IXSBF vs IMMB Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, IMMB has a market cap of 115K. Regarding current trading prices, IXSBF is priced at $0.00, while IMMB trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas IMMB's P/E ratio is N/A. In terms of profitability, IXSBF's ROE is +1.90%, compared to IMMB's ROE of -0.09%. Regarding short-term risk, IXSBF is more volatile compared to IMMB. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check IMMB's competition here
IXSBF vs FOGCF Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, FOGCF has a market cap of 97.2K. Regarding current trading prices, IXSBF is priced at $0.00, while FOGCF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas FOGCF's P/E ratio is -0.00. In terms of profitability, IXSBF's ROE is +1.90%, compared to FOGCF's ROE of +3.99%. Regarding short-term risk, IXSBF is more volatile compared to FOGCF. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check FOGCF's competition here
IXSBF vs MDIN Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, MDIN has a market cap of 90.3K. Regarding current trading prices, IXSBF is priced at $0.00, while MDIN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas MDIN's P/E ratio is N/A. In terms of profitability, IXSBF's ROE is +1.90%, compared to MDIN's ROE of +0.36%. Regarding short-term risk, IXSBF is more volatile compared to MDIN. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check MDIN's competition here
IXSBF vs OXIHF Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, OXIHF has a market cap of 72K. Regarding current trading prices, IXSBF is priced at $0.00, while OXIHF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas OXIHF's P/E ratio is N/A. In terms of profitability, IXSBF's ROE is +1.90%, compared to OXIHF's ROE of +3.30%. Regarding short-term risk, IXSBF and OXIHF have similar daily volatility (196.04).Check OXIHF's competition here
IXSBF vs LGNXZ Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, LGNXZ has a market cap of 42.1K. Regarding current trading prices, IXSBF is priced at $0.00, while LGNXZ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas LGNXZ's P/E ratio is N/A. In terms of profitability, IXSBF's ROE is +1.90%, compared to LGNXZ's ROE of +0.16%. Regarding short-term risk, IXSBF is more volatile compared to LGNXZ. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check LGNXZ's competition here
IXSBF vs DECN Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, DECN has a market cap of 35.5K. Regarding current trading prices, IXSBF is priced at $0.00, while DECN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas DECN's P/E ratio is N/A. In terms of profitability, IXSBF's ROE is +1.90%, compared to DECN's ROE of -103.89%. Regarding short-term risk, IXSBF is more volatile compared to DECN. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check DECN's competition here
IXSBF vs SPPH Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, SPPH has a market cap of 29.4K. Regarding current trading prices, IXSBF is priced at $0.00, while SPPH trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas SPPH's P/E ratio is -0.03. In terms of profitability, IXSBF's ROE is +1.90%, compared to SPPH's ROE of -0.50%. Regarding short-term risk, IXSBF and SPPH have similar daily volatility (196.04).Check SPPH's competition here
IXSBF vs OMHE Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, OMHE has a market cap of 29.3K. Regarding current trading prices, IXSBF is priced at $0.00, while OMHE trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas OMHE's P/E ratio is N/A. In terms of profitability, IXSBF's ROE is +1.90%, compared to OMHE's ROE of +0.73%. Regarding short-term risk, IXSBF is more volatile compared to OMHE. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check OMHE's competition here
IXSBF vs LGNDZ Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, LGNDZ has a market cap of 26.1K. Regarding current trading prices, IXSBF is priced at $0.00, while LGNDZ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas LGNDZ's P/E ratio is N/A. In terms of profitability, IXSBF's ROE is +1.90%, compared to LGNDZ's ROE of +0.16%. Regarding short-term risk, IXSBF is more volatile compared to LGNDZ. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check LGNDZ's competition here
IXSBF vs HADV Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, HADV has a market cap of 24.1K. Regarding current trading prices, IXSBF is priced at $0.00, while HADV trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas HADV's P/E ratio is N/A. In terms of profitability, IXSBF's ROE is +1.90%, compared to HADV's ROE of +0.42%. Regarding short-term risk, IXSBF is more volatile compared to HADV. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check HADV's competition here
IXSBF vs SCRCQ Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, SCRCQ has a market cap of 14.1K. Regarding current trading prices, IXSBF is priced at $0.00, while SCRCQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas SCRCQ's P/E ratio is -0.01. In terms of profitability, IXSBF's ROE is +1.90%, compared to SCRCQ's ROE of +1.63%. Regarding short-term risk, IXSBF and SCRCQ have similar daily volatility (196.04).Check SCRCQ's competition here
IXSBF vs TSTS Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, TSTS has a market cap of 12.8K. Regarding current trading prices, IXSBF is priced at $0.00, while TSTS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas TSTS's P/E ratio is N/A. In terms of profitability, IXSBF's ROE is +1.90%, compared to TSTS's ROE of +2.32%. Regarding short-term risk, IXSBF is more volatile compared to TSTS. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check TSTS's competition here
IXSBF vs VIAP Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, VIAP has a market cap of 10.3K. Regarding current trading prices, IXSBF is priced at $0.00, while VIAP trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas VIAP's P/E ratio is -0.05. In terms of profitability, IXSBF's ROE is +1.90%, compared to VIAP's ROE of +0.65%. Regarding short-term risk, IXSBF is less volatile compared to VIAP. This indicates potentially lower risk in terms of short-term price fluctuations for IXSBF.Check VIAP's competition here
IXSBF vs ALST Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, ALST has a market cap of 10.1K. Regarding current trading prices, IXSBF is priced at $0.00, while ALST trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas ALST's P/E ratio is N/A. In terms of profitability, IXSBF's ROE is +1.90%, compared to ALST's ROE of +0.08%. Regarding short-term risk, IXSBF is more volatile compared to ALST. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check ALST's competition here
IXSBF vs HTPRF Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, HTPRF has a market cap of 8.2K. Regarding current trading prices, IXSBF is priced at $0.00, while HTPRF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas HTPRF's P/E ratio is N/A. In terms of profitability, IXSBF's ROE is +1.90%, compared to HTPRF's ROE of +0.09%. Regarding short-term risk, IXSBF is more volatile compared to HTPRF. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check HTPRF's competition here
IXSBF vs HBOSF Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, HBOSF has a market cap of 7.8K. Regarding current trading prices, IXSBF is priced at $0.00, while HBOSF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas HBOSF's P/E ratio is 0.03. In terms of profitability, IXSBF's ROE is +1.90%, compared to HBOSF's ROE of +6.69%. Regarding short-term risk, IXSBF is more volatile compared to HBOSF. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check HBOSF's competition here
IXSBF vs WPHM Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, WPHM has a market cap of 7.7K. Regarding current trading prices, IXSBF is priced at $0.00, while WPHM trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas WPHM's P/E ratio is N/A. In terms of profitability, IXSBF's ROE is +1.90%, compared to WPHM's ROE of -1.56%. Regarding short-term risk, IXSBF is more volatile compared to WPHM. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check WPHM's competition here
IXSBF vs PXYN Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, PXYN has a market cap of 6.3K. Regarding current trading prices, IXSBF is priced at $0.00, while PXYN trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas PXYN's P/E ratio is N/A. In terms of profitability, IXSBF's ROE is +1.90%, compared to PXYN's ROE of -0.20%. Regarding short-term risk, IXSBF is more volatile compared to PXYN. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check PXYN's competition here
IXSBF vs IYXI Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, IYXI has a market cap of 5.2K. Regarding current trading prices, IXSBF is priced at $0.00, while IYXI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas IYXI's P/E ratio is N/A. In terms of profitability, IXSBF's ROE is +1.90%, compared to IYXI's ROE of +1.71%. Regarding short-term risk, IXSBF is more volatile compared to IYXI. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check IYXI's competition here
IXSBF vs RBII Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, RBII has a market cap of 5K. Regarding current trading prices, IXSBF is priced at $0.00, while RBII trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas RBII's P/E ratio is N/A. In terms of profitability, IXSBF's ROE is +1.90%, compared to RBII's ROE of -0.04%. Regarding short-term risk, IXSBF is more volatile compared to RBII. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check RBII's competition here
IXSBF vs CXBS Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, CXBS has a market cap of 2.7K. Regarding current trading prices, IXSBF is priced at $0.00, while CXBS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas CXBS's P/E ratio is N/A. In terms of profitability, IXSBF's ROE is +1.90%, compared to CXBS's ROE of +0.00%. Regarding short-term risk, IXSBF and CXBS have similar daily volatility (196.04).Check CXBS's competition here
IXSBF vs FSPM Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, FSPM has a market cap of 1.3K. Regarding current trading prices, IXSBF is priced at $0.00, while FSPM trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas FSPM's P/E ratio is N/A. In terms of profitability, IXSBF's ROE is +1.90%, compared to FSPM's ROE of N/A. Regarding short-term risk, IXSBF is more volatile compared to FSPM. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check FSPM's competition here
IXSBF vs GRPI Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, GRPI has a market cap of 1K. Regarding current trading prices, IXSBF is priced at $0.00, while GRPI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas GRPI's P/E ratio is -0.02. In terms of profitability, IXSBF's ROE is +1.90%, compared to GRPI's ROE of +0.09%. Regarding short-term risk, IXSBF is more volatile compared to GRPI. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check GRPI's competition here
IXSBF vs KIARF Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, KIARF has a market cap of 442. Regarding current trading prices, IXSBF is priced at $0.00, while KIARF trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas KIARF's P/E ratio is -0.00. In terms of profitability, IXSBF's ROE is +1.90%, compared to KIARF's ROE of -1.47%. Regarding short-term risk, IXSBF is less volatile compared to KIARF. This indicates potentially lower risk in terms of short-term price fluctuations for IXSBF.Check KIARF's competition here
IXSBF vs AXMP Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, AXMP has a market cap of 409. Regarding current trading prices, IXSBF is priced at $0.00, while AXMP trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas AXMP's P/E ratio is N/A. In terms of profitability, IXSBF's ROE is +1.90%, compared to AXMP's ROE of N/A. Regarding short-term risk, IXSBF is more volatile compared to AXMP. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check AXMP's competition here
IXSBF vs ACGJ Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, ACGJ has a market cap of 324. Regarding current trading prices, IXSBF is priced at $0.00, while ACGJ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas ACGJ's P/E ratio is -0.00. In terms of profitability, IXSBF's ROE is +1.90%, compared to ACGJ's ROE of N/A. Regarding short-term risk, IXSBF is more volatile compared to ACGJ. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check ACGJ's competition here
IXSBF vs NEWG Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, NEWG has a market cap of 226. Regarding current trading prices, IXSBF is priced at $0.00, while NEWG trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas NEWG's P/E ratio is N/A. In terms of profitability, IXSBF's ROE is +1.90%, compared to NEWG's ROE of +0.40%. Regarding short-term risk, IXSBF is more volatile compared to NEWG. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check NEWG's competition here
IXSBF vs MDVLQ Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, MDVLQ has a market cap of 161. Regarding current trading prices, IXSBF is priced at $0.00, while MDVLQ trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas MDVLQ's P/E ratio is N/A. In terms of profitability, IXSBF's ROE is +1.90%, compared to MDVLQ's ROE of -2.39%. Regarding short-term risk, IXSBF is more volatile compared to MDVLQ. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check MDVLQ's competition here
IXSBF vs ISHI Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, ISHI has a market cap of 5. Regarding current trading prices, IXSBF is priced at $0.00, while ISHI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas ISHI's P/E ratio is N/A. In terms of profitability, IXSBF's ROE is +1.90%, compared to ISHI's ROE of N/A. Regarding short-term risk, IXSBF is more volatile compared to ISHI. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check ISHI's competition here
IXSBF vs SYNI Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, SYNI has a market cap of 3. Regarding current trading prices, IXSBF is priced at $0.00, while SYNI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas SYNI's P/E ratio is -0.00. In terms of profitability, IXSBF's ROE is +1.90%, compared to SYNI's ROE of N/A. Regarding short-term risk, IXSBF is more volatile compared to SYNI. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check SYNI's competition here
IXSBF vs TFSHF Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, TFSHF has a market cap of 0. Regarding current trading prices, IXSBF is priced at $0.00, while TFSHF trades at $1.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas TFSHF's P/E ratio is N/A. In terms of profitability, IXSBF's ROE is +1.90%, compared to TFSHF's ROE of N/A. Regarding short-term risk, IXSBF is more volatile compared to TFSHF. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check TFSHF's competition here
IXSBF vs MMCWF Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, MMCWF has a market cap of 0. Regarding current trading prices, IXSBF is priced at $0.00, while MMCWF trades at $0.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas MMCWF's P/E ratio is N/A. In terms of profitability, IXSBF's ROE is +1.90%, compared to MMCWF's ROE of N/A. Regarding short-term risk, IXSBF is more volatile compared to MMCWF. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check MMCWF's competition here
IXSBF vs GHTI Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, GHTI has a market cap of 0. Regarding current trading prices, IXSBF is priced at $0.00, while GHTI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas GHTI's P/E ratio is N/A. In terms of profitability, IXSBF's ROE is +1.90%, compared to GHTI's ROE of N/A. Regarding short-term risk, IXSBF is more volatile compared to GHTI. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check GHTI's competition here
IXSBF vs MDSI Comparison June 2026
IXSBF plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, IXSBF stands at 12.6K. In comparison, MDSI has a market cap of 0. Regarding current trading prices, IXSBF is priced at $0.00, while MDSI trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
IXSBF currently has a P/E ratio of -0.01, whereas MDSI's P/E ratio is N/A. In terms of profitability, IXSBF's ROE is +1.90%, compared to MDSI's ROE of N/A. Regarding short-term risk, IXSBF is more volatile compared to MDSI. This indicates potentially higher risk in terms of short-term price fluctuations for IXSBF.Check MDSI's competition here